Phase I dose escalation study of oral lapatinib in combination with docetaxel in patients with HER2-positive locally advanced or metastatic breast cancer (LAMBC): Initial safety and tolerability results.

Pierre Fumoleau,Florence Dalenc,Audrey Mailliez,Corinne Veyret,Jacques Bonneterre,Cécile Guillemet,Sylvie Zanetta,Cristian Moldovan,Séverine Guiu,Jeremy Skrzypski,Mélanie Gauthier,Bruno Coudert,Nicolas Isambert

Phase I dose escalation study of oral lapatinib in combination with docetaxel in patients with HER2-positive locally advanced or metastatic breast cancer (LAMBC): Initial safety and tolerability results.

2017

Pierre Fumoleau
Florence Dalenc
Audrey Mailliez
Corinne Veyret
Jacques Bonneterre
Cécile Guillemet
Sylvie Zanetta
Cristian Moldovan
Séverine Guiu
Jeremy Skrzypski
Mélanie Gauthier
Bruno Coudert
Nicolas Isambert

e11529 Background: Previous studies evidenced that the combination docetaxel (D) (75 mg/m²) + lapatinib (L) (1,250 mg/d) is well tolerated in heavily pretreated HER2-positive metastatic breast canc...

Keywords:

Pathology
Oncology
Metastatic breast cancer
Lapatinib
Docetaxel
Tolerability
Medicine
Internal medicine
dose escalation
in patient
locally advanced
metastatic breast

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations